中證網訊(記(ji)者 黃淑慧)4月(yue)27日晚間(jian),復星醫藥(600196.SH, 02196.HK) 公布2018年一季(ji)度(du)業績,公司(si)一季(ji)度(du)實現營(ying)業收入人民幣57.19億元,同(tong)比(bi)增長47.38%;經營(ying)性現金流4.66億元,同(tong)比(bi)增長15.84%;扣非凈利潤(run)5.27億元,同(tong)比(bi)增長1.72%。
2018年一季度,復星醫藥(yao)(yao)繼續加(jia)大對單(dan)克(ke)隆抗體生物創(chuang)新藥(yao)(yao)及生物類似藥(yao)(yao)、小分子創(chuang)新藥(yao)(yao)以及推進(jin)一致(zhi)性評價的研發投入(ru),研發費用(yong)為人民幣2.77億(yi)元,同比增長40.28%。
據介(jie)紹 ,2018年初,公(gong)司苯磺酸(suan)氨(an)氯地(di)(di)平片(施力達?)通(tong)過仿(fang)制(zhi)藥(yao)(yao)(yao)一(yi)致性(xing)評價(jia)。此外,復星醫藥(yao)(yao)(yao)生(sheng)(sheng)物(wu)藥(yao)(yao)(yao)平臺復宏漢霖進(jin)(jin)度前(qian)四的重磅(bang)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao)產品全(quan)部(bu)(bu)進(jin)(jin)入(ru)III期(qi)(qi)臨床(chuang)(chuang)(chuang)研(yan)究,領跑國(guo)(guo)內(nei)(nei)單(dan)(dan)抗生(sheng)(sheng)物(wu)藥(yao)(yao)(yao)行業。公(gong)司首個產品HLX01(美(mei)羅華?生(sheng)(sheng)物(wu)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao))作為國(guo)(guo)內(nei)(nei)第一(yi)個以生(sheng)(sheng)物(wu)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao)路(lu)徑(jing)申報上市(shi)的單(dan)(dan)抗生(sheng)(sheng)物(wu)藥(yao)(yao)(yao),已(yi)被納(na)入(ru)優(you)先審評程序(xu)藥(yao)(yao)(yao)品注冊申請名單(dan)(dan),有望打破國(guo)(guo)內(nei)(nei)生(sheng)(sheng)物(wu)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao)空白(bai);HLX02(赫賽汀?生(sheng)(sheng)物(wu)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao))和HLX03(修美(mei)樂(le)?生(sheng)(sheng)物(wu)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao))目(mu)前(qian)皆(jie)已(yi)進(jin)(jin)入(ru)臨床(chuang)(chuang)(chuang)III期(qi)(qi)研(yan)究階段(duan):HLX02于中(zhong)國(guo)(guo)、烏克蘭、歐盟波(bo)蘭、菲律賓(bin)等地(di)(di)全(quan)面開(kai)展臨床(chuang)(chuang)(chuang)III期(qi)(qi)試(shi)驗;HLX03在(zai)國(guo)(guo)內(nei)(nei)率(lv)先啟動(dong)了斑塊(kuai)狀(zhuang)銀屑(xie)病適應癥的臨床(chuang)(chuang)(chuang)III期(qi)(qi)試(shi)驗,臨床(chuang)(chuang)(chuang)試(shi)驗順利(li)開(kai)展;HLX04(安維汀?生(sheng)(sheng)物(wu)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao))I期(qi)(qi)結果顯(xian)示與三地(di)(di)上市(shi)原研(yan)等效,并已(yi)正(zheng)式(shi)啟動(dong)III期(qi)(qi)臨床(chuang)(chuang)(chuang)試(shi)驗。生(sheng)(sheng)物(wu)類(lei)(lei)(lei)似(si)(si)藥(yao)(yao)(yao)項目(mu)全(quan)面開(kai)花(hua)的同時,復宏漢霖的創新項目(mu)也穩步推進(jin)(jin)。截至(zhi)2018年3月(yue),復宏漢霖前(qian)三個創新型單(dan)(dan)抗已(yi)全(quan)部(bu)(bu)獲得中(zhong)國(guo)(guo)大陸、中(zhong)國(guo)(guo)臺灣、美(mei)國(guo)(guo)三地(di)(di)臨床(chuang)(chuang)(chuang)試(shi)驗批準(zhun)。
復星(xing)醫藥表(biao)示,將(jiang)始(shi)終將(jiang)自主創新(xin)作為企業發(fa)展(zhan)的(de)源動力,持續完善“仿創結合”的(de)藥品研(yan)發(fa)體系,公(gong)司(si)已在中國(guo)(guo)、美國(guo)(guo)、印度(du)等建(jian)立了(le)高(gao)(gao)效(xiao)的(de)國(guo)(guo)際化(hua)研(yan)發(fa)團(tuan)隊(dui),形成了(le)全球聯(lian)動的(de)研(yan)發(fa)體系,打造了(le)高(gao)(gao)效(xiao)的(de)化(hua)學創新(xin)藥平臺(tai)、生物(wu)藥平臺(tai)、高(gao)(gao)價值(zhi)仿制藥平臺(tai)及細(xi)胞(bao)免疫平臺(tai)。2018年,公(gong)司(si)將(jiang)繼續堅持“4 IN”(創新(xin)Innovation、國(guo)(guo)際化(hua)Internationalization、整合Integration、智能化(hua)Intelligentization)戰(zhan)略,秉承“內生式(shi)增長、外延(yan)式(shi)擴張、整合式(shi)發(fa)展(zhan)”的(de)發(fa)展(zhan)模式(shi),持續推動公(gong)司(si)穩健(jian)發(fa)展(zhan)。
中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)聲(sheng)明(ming)(ming)(ming):凡本網(wang)(wang)(wang)(wang)注(zhu)明(ming)(ming)(ming)“來源(yuan):中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)證(zheng)(zheng)券報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)”的所有(you)作(zuo)(zuo)品(pin)(pin)(pin),版權均屬于(yu)中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)證(zheng)(zheng)券報、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)。中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)證(zheng)(zheng)券報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)與(yu)作(zuo)(zuo)品(pin)(pin)(pin)作(zuo)(zuo)者聯合(he)聲(sheng)明(ming)(ming)(ming),任何組織(zhi)未經中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)證(zheng)(zheng)券報、中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)以及作(zuo)(zuo)者書面授(shou)權不(bu)得轉(zhuan)載(zai)(zai)、摘編或利用其(qi)它方式使(shi)用上(shang)述作(zuo)(zuo)品(pin)(pin)(pin)。凡本網(wang)(wang)(wang)(wang)注(zhu)明(ming)(ming)(ming)來源(yuan)非(fei)中(zhong)(zhong)(zhong)國(guo)(guo)(guo)(guo)證(zheng)(zheng)券報·中(zhong)(zhong)(zhong)證(zheng)(zheng)網(wang)(wang)(wang)(wang)的作(zuo)(zuo)品(pin)(pin)(pin),均轉(zhuan)載(zai)(zai)自其(qi)它媒體(ti),轉(zhuan)載(zai)(zai)目(mu)的在于(yu)更好服務讀者、傳遞信(xin)息之需,并(bing)不(bu)代表本網(wang)(wang)(wang)(wang)贊同其(qi)觀點,本網(wang)(wang)(wang)(wang)亦不(bu)對其(qi)真(zhen)實性負(fu)責,持(chi)異議(yi)者應與(yu)原出處單位主(zhu)張權利。
特別鏈接:政府部門交易機構證券期貨四所兩司新聞發布平臺友情鏈接版權聲明
關于報社關于本站廣告發布免責條款
中國證券報社版權所有,未經書面授權不得復制或建立鏡像 經營許可證編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved
中國證券報社版權(quan)(quan)所有,未經書(shu)面授權(quan)(quan)不得復制(zhi)或建立(li)鏡像(xiang)
經營許可證(zheng)編號:京B2-20180749 京公網安備0-1
Copyright 2001-2018 China Securities Journal. All Rights Reserved